Inhibition of human breast cancer cell proliferation with estradiol metabolites is as effective as with tamoxifen

Hormone and Metabolic Research

Volumn 36, Issue 5, 2004, Pages 277-280

  Seeger, H ^a   Huober, J ^a   Wallwiener, D ^a   Mueck, A O ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Estradiol metabolites; Human breast cancer cells; Proliferation; Tamoxifen

Indexed keywords

16ALPHA HYDROXYESTRONE; 2 HYDROXYESTRADIOL; 2 HYDROXYESTRIOL; 2 HYDROXYESTRONE; 2 METHOXYESTRADIOL; 2 METHOXYESTRIOL; 2 METHOXYESTRONE; 4 HYDROXYESTRADIOL; 4 HYDROXYESTRONE; 4 HYDROXYTAMOXIFEN; 4 METHOXYESTRADIOL; 4 METHOXYESTRONE; ADENOSINE TRIPHOSPHATE; DRUG METABOLITE; ESTRADIOL; ESTRIOL; ESTROGEN RECEPTOR; ESTRONE DERIVATIVE; TAMOXIFEN; UNCLASSIFIED DRUG;

ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CELL STRAIN MCF 7; CHEMOSENSITIVITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; HUMAN; HUMAN CELL; IC 50; PRIORITY JOURNAL;

BREAST NEOPLASMS; CELL DIVISION; CELL LINE, TUMOR; ESTRADIOL; FEMALE; HUMANS; KINETICS; TAMOXIFEN;

MINK CELL FOCUS-FORMING VIRUS;

EID: 2542588520     PISSN: 00185043     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-814480     Document Type: Article

References (32)

1. Ingle JN. Adjuvant endocrine therapy in postmenopausal breast cancer. Clin Can Res 2003; 9: 480s-485s
2. Riggs BL, Hartmann LC. Selective estrogen-receptor modulators - mechanisms of action and application to clinical practice. N Engl J Med 2003; 348: 618-629
3. Lippert TH, Seeger H, Mueck AO. The impact of endogenous estradiol metabolites on carcinogenesis. Steroids 2000; 65: 357-369
4. Lippert TH, Seeger H, Mueck AO. Metabolism of endogenous estrogens. In: Oettel M, Schillinger E (eds). Estrogens and antiestrogens - handbook of experimental pharmacology. Berlin, Heidelberg, New York: Springer, 1999: 243-271
5. Lippert TH, Seeger H, Mueck AO. Estradiol metabolism during oral and transdermal estradiol replacement therapy in the postmenopause. Horm Metab Res 1998; 30: 598-600
6. Mueck AO, Seeger H, Gräser T, Oettel M, Lippert TH. The effect of postmenopausal hormone replacement therapy and oral contraceptives on the endogenous estradiol metabolism. Horm Metab Res 2001; 33: 744-747
7. Lippert TH, Seeger H, Mueck AO. Estrogens and the cardiovascular system: role of estradiol metabolites in hormone replacement therapy. Climacteric 1999; 1: 296-301
8. Andreotti PE, Thornthwaite JT, Morse IS. ATP Tumor Chemosensitivity Assay. In: Stanley PE, Kricka LJ (eds). Bioluminescence and Chemiluminescence: Current Status. Chichester: J. Wiley & Sons, 1991: 417-420
9. Zhu BT, Connery AH. Is 2-methoxyestradiol an endogenous metabolite that inhibits mammary carcinogenesis. Cancer Res 1998; 58: 2269-2277
10. Mukhopadhyay T, Roth JA. Induction of apoptosis in human lung cancer cells after wild type p53 activation by 2-methoxyestradiol. Oncogene 1997; 14: 379-384
11. Cushman M, He HM, Katzenellenbogen JA, Lin CM, Hamel E. Synthesis, antitubulin and antimitotic activity and cytotoxicity of analogs of 2-methoxyestradiol, an endogenous mammalian metabolite of estradiol that inhibits tubulin polymerization by binding to the colchicin binding site. J Med Chem 1995; 38: 2041-2049
12. Seegers JC, Aveling ML, van Aswegen CH, Cross M, Koch F, Joubert WS. The cytotoxic effects of estradiol 17 β, catecholestradiols and methoxyestradiols on dividing MCF-7 and HeLa cells. J Steroid Biochem 1989; 32: 797-809
13. Lottering ML, de Kock M, Viljoen TC, Grobler CJ, Seegers JC. 17 beta-estradiol metabolites affect some regulators of the MCF-7 cell cycles. Cancer Lett 1996; 110: 181-186
14. Klauber N, Parangi S, Flynn E, Hamel E, D'Amato RJ. Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyoestradiol and taxol. Cancer Res 1997; 57: 81-86
15. Fotsis T, Zhang Y, Pepper MS, Adlercreutz H, Montesano R, Nawroth PP, Schweigerer L. The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth. Nature 1994; 368: 237-239
16. Lippert C, Seeger H, Mueck AO, Lippert TH. The effects of A-ring and D-ring metabolites of estradiol on the proliferation of vascular endothelial cells. Life Sciences 2000; 67: 1653-1658
17. Roy D, Weisz J, Liehr LG. The O-methylation of 4-hydroxyestradiol is inhibited by 2-hydroxyestradiol: implications for estrogen-induced carcinogenesis. Carcinogenesis 1990; 11: 459-462
18. Kabat GC, Chang CJ, Sparano JA, Sepkovic DW, Hu XP, Khalil A, Rosenblatt R, Bradlow HL. Urinary estrogen metabolites and breast cancer: A case-control study. Cancer Epidemiol Biomarkers Prev 1997; 6: 505-509
19. Meilahn EN, de Stavol B, Allen DS, Fentiman I, Bradlow HL, Stepkovic DW, Kuller LH. Do urinary oestrogen metabolites predict breast cancer? Guernsey III cohort follow-up. Br J Cancer 1998; 78: 1250-1255
20. Muti P, Bradlow HL, Micheli A, Krogh V, Freudenheim JL, Schunemann HJ, Stanulla M, Yang J, Sepkovic DW, Trevisan M, Berrino F. Estrogen metabolism and risk of breast cancer: a prospective study of 2:16alpha-hydroxyestrone ratio in premenopausal and postmenopausal women. Epidemiology 2000; 11: 635-640
21. Bradlow HL, Telang NT, Sepkovic DW, Osborne MP. 2-Hydroxyestrone: the 'good' estrogen. J Endocrinology 1996; 150: S259-S265
22. Jordan JC. The past, present, and future of selective estrogen receptor modulation. Ann NY Acad Sci 2001; 949: 72-79
23. Coletta AA, Benson JR, Baum M. Alternative mechanisms of action of anti-oestrogens. Breast Cancer Res Treat 1994; 31: 5-9
24. Butta A, MacLennan K, Flanders KC, Sacks NPM, Smith I, McKinna A, Dowsett M, Wakefield LM, Sporn MB, Baum M, Colletta AA. Induction of transforming growth factor β 1 in human breast cancer in vivo following tamoxifen treatment. Cancer Res 1992; 52: 4261-4264
25. Cullen KJ, Lippmann ME, Chow D, Hill S, Rosen N, Zwiebel JA. Insulin-like growth factor-II overexpression in MCF-7 cells induces phenotypic changes associated with malignant progression. Mol Endocrinol 1992; 6: 91-100
26. Coradini D, Biffi A, Cappelletti V, di Fronzo G. Activity of tamoxifen and new antiestrogens on estrogen receptor positive and negative breast cancer cells. Anticancer Res 1994; 14: 1059-1064
27. Shen F, Xue X, Weber G. Tamoxifen and genistein synergistically down-regulate signal transduction and proliferation in estrogen receptor-negative human breast carcinoma MDA-MB-435 cells. Anticancer Res 1999; 19: 1657-1662
28. Aldous WK, Marean AJ, DeHart MJ, Matej LA, Moore KH. Effects of tamoxifen on telomerase activity in breast carcinoma cell lines. Cancer 1999; 85: 1523-1529
29. Swain SM. Tamoxifen for patients with estrogen receptor-negative breast cancer. J Clinical Oncology 2001; 19: 93s-97s
30. Seeger H, Wallwiener D, Mueck AO. The effect of progesterone and synthetic progestins on serum- and estradiol-stimulated proliferation of human breast cancer cells. Horm Metab Res 2003; 35: 76-80
31. Fuchs WS, Leary WP, van der Meer MJ, Gay S, Witschital K, van Nieciecki A. Pharmacokinetics and bioavailability of tamoxifen in postmenopausal healthy women. Arzneimittelforschung 1996; 46: 418-422
32. Miller KD, Haney LG, Pribluda VS, Sledge GW. A phase II safety, pharmacokinetic and pharmacodynamic study of Panzem (2-methoxyestradiol) in patients with refractory metastatic breast cancer. 37th Congress of the American Society of Clinical Oncology, San Francisco, May 12-15, 2001, Abstract No. 170.